Quick Takeaways
- Mark Alan Goldberg has 4 issuer positions tracked on this page.
- Estimated disclosed ownership value: $108,975.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Mark Alan Goldberg
- Location
- Lexington, MA
- Summary
- The estimated net worth of Mark Alan Goldberg is at least $108,975 dollars as of 21 Jul 2025. Mark Alan Goldberg is the Director of GLYCOMIMETICS INC and owns shares of CRESCENT BIOPHARMA, INC. (CBIO) stock worth about $109K.
- Signature
- /s/ Melissa Masse, Attorney-in-Fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Mark Alan Goldberg and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: GLYCOMIMETICS INC ($108,975).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original FilingOwnership of Mark Alan Goldberg
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| CBIO | GLYCOMIMETICS INC | Director | $108,975 | 01 May 2024 | ||
| BPMC | Blueprint Medicines Corp | Director | $0 | 17 Jul 2025 | ||
| IMGN | ImmunoGen, Inc. | Director | $0 | 12 Feb 2024 | ||
| IDRA | IDERA PHARMACEUTICALS, INC. | Director | 23 Jun 2022 |
Insider Transactions Reported by Mark Alan Goldberg:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.